Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease.

Matthew R SmithShibu ThomasMichael GormleySimon ChowdhuryDavid OlmosStephane Marie OudardFelix Y FengYashoda RajpurohitKaren UrtishakDeborah S RicciBrendan RooneyAngela Lopez-GitlitzMargaret YuAlexander W Wyatt Mark Li Gerhardt AttardEric J Small

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Apalutamide plus ADT did not increase detectable AR/non-AR aberrations over ADT alone. Detectable ctDNA, AR aberrations, and TP53/BRCA2 inactivation at EOST were associated with poor outcomes in patients treated with first subsequent androgen signaling inhibitor.

Keyphrases

copy number
small cell lung cancer
squamous cell carcinoma
type diabetes
stem cells
metabolic syndrome
bone marrow
newly diagnosed
cell therapy
weight loss
circulating tumor cells
glycemic control